Enlarged Brain Choroid Plexus Emerges as a New Imaging Fingerprint of Metabolic Syndrome

Deep inside each of the brain’s four fluid-filled ventricles sits a small, frilly structure called the choroid plexus, a tuft of blood vessels wrapped in specialized epithelial cells that has long been dismissed as little more than a factory for cerebrospinal fluid. A new neuroimaging study now suggests that this unassuming organ may swell in people with metabolic syndrome, the dangerous cluster of abdominal obesity, high blood sugar, elevated triglycerides, low

The choroid plexus has historically been treated as a passive plumbing fixture of the brain, but modern neuroscience has progressively revised that view. The structure is composed of a core of fenestrated capillaries enveloped by a single layer of cuboidal epithelial cells joined by tight junctions, and it is this epithelial barrier that constitutes the blood–cerebrospinal fluid barrier, one of the brain’s principal interfaces with the circulating blood. Beyond secreting the bulk of cerebrospinal fluid, the plexus transports nutrients, clears metabolic waste products, and releases signaling molecules such as growth factors and cytokines that influence the neural environment. Because it sits at the crossroads of the periphery and the central nervous system, the choroid plexus is increasingly viewed as a sensitive recorder of systemic physiological states, which is precisely why investigators have begun measuring its size on routine magnetic resonance images as a potential biomarker of disease.

The rationale for linking this structure to metabolic syndrome rests on well-documented biology. Obesity and insulin resistance are accompanied by chronic low-grade inflammation, elevated circulating cytokines, endothelial dysfunction, and altered lipid profiles, all of which can perturb barrier tissues. The choroid plexus is richly vascularized and densely populated with endothelial cells, making it a plausible site where peripheral metabolic stress might first register as structural change. Animal work has shown that the plexus responds to systemic inflammatory signals, and in humans it has been reported to enlarge in mild cognitive impairment even after accounting for overall brain shrinkage, as well as in Alzheimer’s disease and Parkinson’s disease. Enlargement of the plexus in these contexts is thought by some researchers to reflect epithelial proliferation, stromal change, or accumulation of iron and other deposits, although the exact cellular basis remains an open question. What the new study adds is a test of whether this same structural signature appears in a purely metabolic disorder, before overt neurodegeneration has taken hold.

Methodologically, the study illustrates how automated segmentation is transforming quantitative neuroimaging. The researchers trained a three-dimensional nnU-Net, a widely used self-configuring deep learning framework, to delineate the choroid plexus from standard three-dimensional T1-weighted images. This approach removes much of the labor and inter-rater variability that plagued manual tracing of small structures, and it makes it feasible to measure the plexus in hundreds of participants within a single study. Normalizing plexus volume to estimated total intracranial volume is an important safeguard, since head size varies substantially across individuals and raw volumes can be misleading. Estimated total intracranial volume itself is typically derived from skull dimensions on the same scans, providing a stable proxy for maximal premorbid brain size that is largely unaffected by disease-related atrophy in adulthood.

The cohort of 211 participants, divided into 73 individuals meeting metabolic syndrome criteria and 138 controls, was assembled under diagnostic criteria issued by the Chinese Medical Association Diabetes Branch, which define the syndrome through combinations of elevated body mass index, fasting glucose, blood pressure, triglycerides, and reduced high-density lipoprotein cholesterol. This matters because metabolic syndrome definitions differ across international bodies, with some emphasizing waist circumference and others using body mass index, so the composition of the syndrome in this cohort may differ subtly from studies using National Cholesterol Education Program or International Diabetes Federation criteria. The participants were drawn from a larger pool of 625 individuals recruited prospectively between 2021 and 2024, and diagnoses were made by experienced endocrinologists with identifying information obscured to reduce bias.

The central finding, that participants with metabolic syndrome showed a larger choroid plexus relative to intracranial volume than controls, gains credibility from the fact that the association survived correction for multiple comparisons. The researchers applied false discovery rate correction, a statistical procedure that controls the expected proportion of false positives when many hypotheses are tested simultaneously, an essential step given the number of metabolic components and cognitive domains examined. Among the individual components of the syndrome, only low high-density lipoprotein cholesterol remained independently associated with plexus enlargement after full adjustment. This specificity is intriguing. High-density lipoprotein cholesterol is involved in reverse cholesterol transport and has anti-inflammatory and endothelial-protective properties, and low levels are a recognized cardiovascular risk factor. A link between reduced HDL-C and choroid plexus size could reflect lipid-mediated effects on the plexal vasculature or epithelium, though the cross-sectional design cannot distinguish cause from consequence.

Equally instructive is what did not hold up. In unadjusted analyses, the choroid plexus ratio appeared to correlate with several cognitive-motor domains, but once demographic confounders and ventricular size were taken into account, these associations dissolved. This pattern is a textbook illustration of why multivariable adjustment matters in neuroimaging research. Age, sex, education, and brain atrophy all influence both plexus size and cognitive performance, and ventricular enlargement can mechanically accompany plexus measurement changes. Without adjustment, a biomarker can appear cognitively relevant when it is merely a proxy for aging or brain volume loss. The authors’ transparency about this loss of significance is a strength of the work rather than a weakness, and it tempers any temptation to overinterpret the plexus as a direct marker of cognitive decline.

The machine learning component of the study adds a complementary perspective. The Boruta algorithm, a wrapper method built on random forests, evaluates every candidate feature against shuffled copies of itself to determine which variables carry genuine information. In this cohort it singled out three features: the choroid plexus ratio, white matter hyperintensity volume normalized to intracranial volume, and body mass index. White matter hyperintensities, visible as bright regions on T2-weighted fluid-attenuated sequences, are a well-established marker of cerebral small vessel disease and are known to accumulate in hypertension, diabetes, and aging. Their selection alongside the plexus measure suggests that the two may capture overlapping or complementary facets of cerebrovascular health. The combined model achieved an area under the receiver operating characteristic curve of 0.787 for identifying participants in the lowest quartile of global cognitive-motor performance, a level conventionally described as acceptable but not outstanding discrimination for a clinical screening tool.

The DeLong comparisons are particularly revealing. DeLong’s test is a standard method for assessing whether differences between correlated receiver operating characteristic curves are statistically significant, and here it showed that the three-variable model did not meaningfully outperform either the choroid plexus ratio alone, which achieved 0.742, or the combination of white matter hyperintensity burden and body mass index, which achieved 0.729. The corrected p-values of 0.084 fall just short of conventional thresholds, indicating that the apparent added value of combining markers was not statistically robust in this sample. In practical terms, no single variable or pair of variables clearly dominated, and the modest sample size limits the precision of these comparisons. This underscores that the study is exploratory and hypothesis-generating rather than definitive.

Several limitations deserve emphasis when situating these findings in the broader literature. The cross-sectional design captures a single moment in time and cannot establish whether plexus enlargement precedes, accompanies, or follows metabolic dysfunction. The cohort was recruited from a single hospital population in China, which may limit generalizability to other ethnic and demographic groups, particularly given that metabolic syndrome criteria and body composition norms vary across populations. The cognitive-motor composite aggregated performance across multiple tests, and the definition of lower performance as the lowest quartile is a relative rather than absolute threshold. Furthermore, the choroid plexus is a small structure, and even excellent segmentation algorithms can be challenged by partial volume effects, motion artifacts, and anatomical variability, though the automated approach used here represents the current state of the art.

Looking forward, the most valuable next step would be longitudinal follow-up of individuals with and without metabolic syndrome, tracking choroid plexus volume alongside inflammatory markers, lipid profiles, and cognitive trajectories. Such studies could clarify whether plexus enlargement is a stable trait of metabolic dysregulation, a dynamic response that tracks with glycemic or lipid control, or an early harbinger of neurodegenerative change. Intervention studies, including weight loss, exercise, or lipid-modifying therapies, could test whether the plexus responds to metabolic improvement. If future work confirms that the choroid plexus functions as an imaging window onto the brain’s interface with systemic metabolism, it could eventually complement established markers such as white matter hyperintensity burden in the risk stratification of patients with metabolic disease, offering clinicians an additional, readily obtainable signal from scans that are already part of routine care.

Subject of Research: Choroid plexus volume as a neuroimaging marker of metabolic syndrome and cognitive-motor performance

Article Title: Choroid plexus volume in metabolic syndrome: a cross-sectional neuroimaging study

Article References: Huo, X., Chen, T., Cheng, Z., Chen, B., Zhang, F., Chen, Y., Liang, P., Zhang, N., Che, Y., Liang, C., Guo, L., & Li, M. (2026). Choroid plexus volume in metabolic syndrome: a cross-sectional neuroimaging study. Frontiers in Neurology, 17, Article 1912049. https://doi.org/10.3389/fneur.2026.1912049

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1912049

Keywords: choroid plexus, metabolic syndrome, HDL cholesterol, neuroimaging, MRI segmentation, cognitive function, white matter hyperintensities, glymphatic system, neuroinflammation, cross-sectional study, nnU-Net, blood-brain barrier